ATE258188T1 - Retro-, inverso-, und retro-inverso synthetische peptidanaloge - Google Patents
Retro-, inverso-, und retro-inverso synthetische peptidanalogeInfo
- Publication number
- ATE258188T1 ATE258188T1 AT93918788T AT93918788T ATE258188T1 AT E258188 T1 ATE258188 T1 AT E258188T1 AT 93918788 T AT93918788 T AT 93918788T AT 93918788 T AT93918788 T AT 93918788T AT E258188 T1 ATE258188 T1 AT E258188T1
- Authority
- AT
- Austria
- Prior art keywords
- retro
- inverso
- synthetic peptide
- analogues
- peptide analogs
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 229960005486 vaccine Drugs 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0212—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -N-C-N-C(=0)-, e.g. retro-inverso peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/825—Bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPL437492 | 1992-08-27 | ||
PCT/AU1993/000441 WO1994005311A1 (en) | 1992-08-27 | 1993-08-27 | Retro-, inverso-, and retro-inverso synthetic peptide analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE258188T1 true ATE258188T1 (de) | 2004-02-15 |
Family
ID=3776390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93918788T ATE258188T1 (de) | 1992-08-27 | 1993-08-27 | Retro-, inverso-, und retro-inverso synthetische peptidanaloge |
Country Status (14)
Country | Link |
---|---|
US (1) | US6261569B1 (de) |
EP (1) | EP0667786B1 (de) |
JP (1) | JP4116072B2 (de) |
KR (1) | KR950702839A (de) |
CN (1) | CN1091138A (de) |
AT (1) | ATE258188T1 (de) |
AU (1) | AU667578B2 (de) |
BR (1) | BR9306984A (de) |
CA (1) | CA2143823C (de) |
DE (1) | DE69333397T2 (de) |
HU (1) | HUT71860A (de) |
NZ (1) | NZ255256A (de) |
OA (1) | OA10129A (de) |
WO (1) | WO1994005311A1 (de) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9306984A (pt) | 1992-08-27 | 1999-01-12 | Deakin Res Ltd | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo |
AUPM411994A0 (en) * | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
AU699757B2 (en) * | 1994-02-25 | 1998-12-17 | Bioclones (Pty) Ltd | Synthetic inverso or retro-inverso T-cell epitopes |
FR2717081B1 (fr) * | 1994-03-14 | 1996-06-21 | Centre Nat Rech Scient | Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro. |
US5814316A (en) * | 1994-08-05 | 1998-09-29 | Wisconsin Alumni Research Foundation | Compound to mimick a naturally occurring peptide's effect |
FR2737209B1 (fr) | 1995-07-25 | 1997-09-19 | Bio Merieux | Peptide capable d'etre reconnu par des anticorps reconnaissant l'antigene c33 du virus de l'hepatite c |
IT1277057B1 (it) * | 1995-12-11 | 1997-11-04 | Tecnogen Scpa | Peptidi antigenici migliorati |
WO1997021728A1 (en) | 1995-12-12 | 1997-06-19 | Karolinska Innovations Ab | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
FR2763071B1 (fr) * | 1997-05-07 | 2003-05-16 | Centre Nat Rech Scient | Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic |
US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US7179892B2 (en) * | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
EP0947525A1 (de) * | 1998-03-27 | 1999-10-06 | Innogenetics N.V. | Epitope in der viralen Hüllproteine und spezifische Antikörper gegen diese Epitope: Verwendung für die detektion von viralantigene im empfängergewebe |
US7491796B1 (en) * | 1998-11-19 | 2009-02-17 | Merrion Research Iii Limited | Retro-inversion peptides that target GIT receptors and related methods |
US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20070135337A2 (en) * | 1999-11-29 | 2007-06-14 | Neurochem (International) Limited | Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases |
US20020094335A1 (en) * | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
US7449544B2 (en) * | 1999-11-30 | 2008-11-11 | Cyclacel Limited | p21 peptides |
EP1174506A1 (de) * | 2000-06-28 | 2002-01-23 | Stichting Dienst Landbouwkundig Onderzoek | C-terminales Erns-Peptide und Analoge davon |
DE10054055A1 (de) * | 2000-10-31 | 2002-05-23 | Nmi Univ Tuebingen | Verfahren zur Analyse von Proteinen |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
IL140881A0 (en) * | 2001-01-14 | 2002-02-10 | Katz Emil Israel | A method for identification and quantification of proteins in a biopsy or other tissue sample and a kit for use thereof |
WO2002089731A2 (en) * | 2001-05-03 | 2002-11-14 | Stanford University | Agents for treatment of hcv and methods of use |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
MY139983A (en) * | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
US7460960B2 (en) * | 2002-05-10 | 2008-12-02 | Epitome Biosystems, Inc. | Proteome epitope tags and methods of use thereof in protein modification analysis |
US7618788B2 (en) * | 2002-05-10 | 2009-11-17 | Millipore Corporation | Proteome epitope tags and methods of use thereof in protein modification analysis |
US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
ATE426575T1 (de) * | 2003-01-07 | 2009-04-15 | Univ Ramot | Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben |
CN1745175A (zh) * | 2003-02-01 | 2006-03-08 | 神经实验室有限公司 | 自动免疫产生针对可溶性A-β的抗体 |
TWI306458B (en) | 2003-05-30 | 2009-02-21 | Elan Pharma Int Ltd | Humanized antibodies that recognize beta amyloid peptide |
CA2530927A1 (en) | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
EP1663199B1 (de) * | 2003-09-25 | 2013-04-03 | Tel Aviv University Future Technology Development L.P. | Zusammensetzungen und diese verwendende verfahren zur behandlung von amyloid-bedingten erkrankungen |
WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
US8007847B2 (en) * | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
US7259145B2 (en) * | 2004-07-07 | 2007-08-21 | The Research Foundation Of State University Of New York | Mechanically activated channel blocker |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
US8568637B2 (en) * | 2004-08-02 | 2013-10-29 | Ramot At Tel-Aviv University Ltd. | Method of forming a fiber made of peptide nanostructures |
EP1793816B1 (de) * | 2004-08-19 | 2012-01-04 | Tel Aviv University Future Technology Development L.P. | Zusammensetzungen zur behandlung von amyloid-assoziierten erkrankungen |
WO2006027780A2 (en) * | 2004-09-08 | 2006-03-16 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
AR052051A1 (es) | 2004-12-15 | 2007-02-28 | Neuralab Ltd | Anticuerpos ab humanizados usados en mejorar la cognicion |
US8080517B2 (en) | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
US8445007B2 (en) | 2005-09-22 | 2013-05-21 | Medivas, Llc | Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use |
WO2007043048A2 (en) * | 2005-10-11 | 2007-04-19 | Ramot At Tel Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
US7879212B2 (en) | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
ES2809167T3 (es) | 2006-01-17 | 2021-03-03 | Forsgren Arne | Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE) |
EP1826199A1 (de) | 2006-02-27 | 2007-08-29 | Technische Universität Wien | Modifizierte Aminosäuren |
US7855057B2 (en) * | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
US7674772B2 (en) * | 2006-03-31 | 2010-03-09 | Queen's University At Kingston | Compositions and methods for treating atherosclerosis |
WO2009017467A1 (en) | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
WO2008124768A1 (en) | 2007-04-09 | 2008-10-16 | The General Hospital Corporation | Hemojuvelin fusion proteins and uses thereof |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
PL2352508T3 (pl) | 2008-10-17 | 2014-09-30 | Dana Farber Cancer Inst Inc | Peptydy domeny cytoplazmatycznej MUC-1 jako inhibitory nowotworu |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
DE102008037564A1 (de) * | 2008-11-19 | 2010-05-20 | Forschungszentrum Jülich GmbH | Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
ES2564265T3 (es) | 2009-03-09 | 2016-03-21 | Ramot At Tel-Aviv University Ltd. | Composiciones para prevención y tratamiento de enfermedades neurodegenerativas |
WO2011008863A2 (en) * | 2009-07-14 | 2011-01-20 | Lucia Irene Gonzalez | Stereoisomer peptides and their polymer conjugates for hiv disease |
US9849174B2 (en) | 2009-11-20 | 2017-12-26 | The Board Of Regents Of The University Of Texas System | Methods and compositions related to immunogenic fibrils |
WO2011100688A1 (en) | 2010-02-12 | 2011-08-18 | Dana-Farber Cancer Institute, Inc. | Improved antagonists of muc1 |
WO2011115819A2 (en) | 2010-03-15 | 2011-09-22 | Genus Oncology, Llc | Small molecule inhibitors of muc1 and methods of identifying the same |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
CA2807036C (en) | 2010-10-14 | 2018-01-16 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
MX2013005413A (es) | 2010-11-15 | 2014-02-27 | Univ Ramot | Analogos de dipeptidos para el tratamiento de afecciones asociadas con la formacion de fibrillas amiloides. |
US9211313B2 (en) | 2011-01-14 | 2015-12-15 | The Research Foundation Of State University Of New York | Methods and compound to inhibit Ca2+ permeable cation conductance |
WO2012135081A2 (en) | 2011-03-25 | 2012-10-04 | Children's Medical Center Corporation | Lin28-mediated control of let-7 biogenesis |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
WO2013026015A1 (en) | 2011-08-18 | 2013-02-21 | Dana-Farber Cancer Institute, Inc. | Muc1 ligand traps for use in treating cancers |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
CA2859777C (en) | 2012-01-09 | 2020-06-30 | Serpin Pharma, Llc | Serine protease inhibitor (serpin) peptides and methods thereof |
US9044421B2 (en) | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
JP5918909B2 (ja) | 2012-06-25 | 2016-05-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 標的化治療薬 |
ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
WO2014045126A2 (en) | 2012-09-18 | 2014-03-27 | Uti Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
US9789156B2 (en) | 2013-03-11 | 2017-10-17 | Dana-Farber Cancer Institute, Inc. | Combination anti-human epidermal growth factor receptor 2 (anti-HER2) cancer therapy using mucin 1 (MUC1) peptides and hemotherapeutics |
US9572855B2 (en) | 2013-03-11 | 2017-02-21 | Dana-Farber Cancer Institute, Inc. | Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics |
PL2968470T3 (pl) | 2013-03-12 | 2021-05-31 | The General Hospital Corporation | Zmodyfikowane białka stanowiące substancję hamującą rozwój przewodów müllera (mis) i ich zastosowania do leczenia chorób |
HRP20230527T1 (hr) | 2013-03-15 | 2023-08-04 | GLAdiator Biosciences, Inc. | Gla domene kao ciljni agensi |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
AU2014301631A1 (en) | 2013-06-26 | 2015-08-27 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3194446B1 (de) | 2014-09-18 | 2022-10-26 | Cedars-Sinai Medical Center | Zusammensetzungen und verfahren zur behandlung von fibrose |
CN104744564B (zh) | 2015-03-13 | 2017-07-28 | 天津托普泰克生物科技有限公司 | 抗乙型肝炎病毒x蛋白多肽药物 |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
CN107708718B (zh) | 2015-04-22 | 2022-01-11 | 西达-赛奈医疗中心 | 用于治疗2型糖尿病的肠内递送的苦味寡肽 |
CN113429455A (zh) | 2015-08-28 | 2021-09-24 | 赛品制药有限责任公司 | 用于疾病治疗的方法 |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
US10774122B2 (en) | 2017-03-21 | 2020-09-15 | The Regents Of The University Of Michigan | ERG targeted therapy |
US11878047B2 (en) | 2018-01-03 | 2024-01-23 | Sapience Therapeutics, Inc. | ATF5 peptide variants and uses thereof |
JP2021513367A (ja) | 2018-02-12 | 2021-05-27 | ダイアベーツ−フリー, インコーポレイテッド | 改善されたアンタゴニスト的抗ヒトcd40モノクローナル抗体 |
CN112739367A (zh) | 2018-09-10 | 2021-04-30 | 肺疾治疗公司 | Cav-1蛋白的修饰的肽片段及其在纤维化治疗中的用途 |
WO2020102454A1 (en) | 2018-11-13 | 2020-05-22 | Regents Of The University Of Minnesota | Cd40 targeted peptides and uses thereof |
CN111233975A (zh) * | 2018-11-28 | 2020-06-05 | 复旦大学 | 可靶向整合素的多肽mn及其在制备肿瘤靶向药物中的应用 |
CN115343485B (zh) * | 2022-10-18 | 2023-01-06 | 天津德祥生物技术股份有限公司 | 血型抗原三糖偶联物在血型抗体检测中的应用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4010260A (en) * | 1975-07-28 | 1977-03-01 | Ayerst Mckenna & Harrison Ltd. | Derivatives of retro-enantio-somatostatin, intermediates therefor, and process therefor |
CA1040623A (en) * | 1975-08-28 | 1978-10-17 | Hans U. Immer | Derivatives of retro-enantio-somatostatin, intermediates therefor and process therefor |
IT1190891B (it) | 1982-06-24 | 1988-02-24 | Anic Spa | Metodo per la sintesi in fase solida di polipeptidi retroinvertiti |
IT1164225B (it) * | 1983-05-13 | 1987-04-08 | Anic Spa | Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione |
IT1206339B (it) * | 1984-01-13 | 1989-04-14 | Anic Spa | Analoghi retro-invertiti esapeptidici c-terminali della sostanza p. |
IT1178789B (it) * | 1984-12-21 | 1987-09-16 | Assorenti | Peptidi retro-invertiti analoghi del potenziatore della bradichinina bpp 5a |
IT1184164B (it) * | 1985-03-19 | 1987-10-22 | Eniricerche Spa | Triptidi ad azione ipotensiva e procedimento per la loro sintesi |
US4709017A (en) * | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
WO1987007616A1 (en) * | 1986-06-12 | 1987-12-17 | Biogen N.V. | Peptides involved in the pathogenesis of hiv infection |
IT1216908B (it) | 1987-03-19 | 1990-03-14 | Eniricerche Spa | Analoghi retro-inversi della timopentina e dei suoi frammenti, il metodo per la loro sintesi ed il loro impiego per la preparazionedi composizioni farmaceutiche. |
FR2615104B1 (fr) * | 1987-05-14 | 1989-08-18 | Centre Nat Rech Scient | Nouvelle protease de plasmodium falciparum, anticorps diriges contre cette protease, substrats peptidiques specifiques de ladite protease, et leur utilisation comme medicament contre le paludisme |
DE68917126T2 (de) | 1988-02-01 | 1995-02-02 | Praxis Biolog Inc | T-zellen-epitope als träger für einen konjugierten impfstoff. |
EP0333356A3 (de) * | 1988-03-04 | 1990-12-19 | Biogen, Inc. | Hirudin-Peptide |
GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
IT1226552B (it) | 1988-07-29 | 1991-01-24 | Ellem Ind Farmaceutica | Peptidi immunostimolanti. |
US5000952A (en) | 1988-08-02 | 1991-03-19 | The Board Of Trustees Of The Leland Stanford, Jr. University | Polypeptide pertussis toxin vaccine |
JPH04503660A (ja) * | 1988-12-05 | 1992-07-02 | バイオジェン インコーポレイテッド | 血小板凝集抑制の方法及び組成物 |
IT1227907B (it) * | 1988-12-23 | 1991-05-14 | Eniricerche S P A Milano Sclav | Procedimento per la sintesi di peptidi retro-inversi e nuovi intermediin tale procedimento |
GB2228262B (en) * | 1989-01-25 | 1992-10-07 | Nat Inst Immunology | Antigenic derivative of gnrh |
IT1230733B (it) * | 1989-06-30 | 1991-10-29 | Eniricerche Spa | Analoghi della timopentina retro invertita a tutti i legami, il metodo per la loro sintesi ed il loro impiego per la preparazione di composizioni farmaceutiche. |
KR940000755B1 (ko) * | 1990-02-16 | 1994-01-29 | 유나이티드 바이오메디칼 인코오포레이티드 | Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드 |
GB9005829D0 (en) | 1990-03-15 | 1990-05-09 | Proteus Biotech Ltd | Synthetic polypeptides |
GB9100468D0 (en) * | 1991-01-09 | 1991-02-20 | Proteus Molecular Design | Improvements in and relating to hormones |
AU648140B2 (en) * | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
JP4233604B2 (ja) | 1991-12-03 | 2009-03-04 | プロセリックス メディスンズ ディベロップメント リミテッド | プリオンタンパク質のフラグメント |
GB9208428D0 (en) | 1992-04-16 | 1992-06-03 | Proteus Molecular Design | Synthetic polypeptides |
MX9304388A (es) * | 1992-07-22 | 1994-03-31 | Proteus Molecular Design | Polopeptido sintetico y proceso para su fabricacion. |
AU4970193A (en) * | 1992-08-26 | 1994-03-15 | Proteus Molecular Design Limited | IPNV vaccine |
BR9306984A (pt) | 1992-08-27 | 1999-01-12 | Deakin Res Ltd | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo |
-
1993
- 1993-08-27 BR BR9306984A patent/BR9306984A/pt not_active Application Discontinuation
- 1993-08-27 US US08/909,551 patent/US6261569B1/en not_active Expired - Lifetime
- 1993-08-27 DE DE69333397T patent/DE69333397T2/de not_active Expired - Lifetime
- 1993-08-27 KR KR1019950700754A patent/KR950702839A/ko not_active Application Discontinuation
- 1993-08-27 WO PCT/AU1993/000441 patent/WO1994005311A1/en active IP Right Grant
- 1993-08-27 JP JP50667194A patent/JP4116072B2/ja not_active Expired - Fee Related
- 1993-08-27 CN CN93118322A patent/CN1091138A/zh active Pending
- 1993-08-27 AU AU49346/93A patent/AU667578B2/en not_active Expired
- 1993-08-27 NZ NZ255256A patent/NZ255256A/en not_active IP Right Cessation
- 1993-08-27 EP EP93918788A patent/EP0667786B1/de not_active Expired - Lifetime
- 1993-08-27 AT AT93918788T patent/ATE258188T1/de not_active IP Right Cessation
- 1993-08-27 HU HU9500571A patent/HUT71860A/hu unknown
- 1993-08-27 CA CA002143823A patent/CA2143823C/en not_active Expired - Lifetime
-
1995
- 1995-02-24 OA OA60615A patent/OA10129A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP0667786B1 (de) | 2004-01-21 |
WO1994005311A1 (en) | 1994-03-17 |
DE69333397D1 (de) | 2004-02-26 |
EP0667786A1 (de) | 1995-08-23 |
EP0667786A4 (de) | 1997-08-06 |
KR950702839A (ko) | 1995-08-23 |
HUT71860A (en) | 1996-02-28 |
AU667578B2 (en) | 1996-03-28 |
CA2143823A1 (en) | 1994-03-17 |
BR9306984A (pt) | 1999-01-12 |
JPH08500829A (ja) | 1996-01-30 |
HU9500571D0 (en) | 1995-04-28 |
AU4934693A (en) | 1994-03-29 |
US6261569B1 (en) | 2001-07-17 |
DE69333397T2 (de) | 2004-12-09 |
JP4116072B2 (ja) | 2008-07-09 |
OA10129A (en) | 1996-12-18 |
NZ255256A (en) | 1997-02-24 |
CA2143823C (en) | 2005-07-26 |
CN1091138A (zh) | 1994-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333397D1 (de) | Retro-, inverso-, und retro-inverso synthetische peptidanaloge | |
MY103182A (en) | Vaccines against acquired immune deficiency syndrome. | |
EA200100425A1 (ru) | Новые способы терапевтической вакцинации | |
IL91007A0 (en) | Synthetic vaccine against aids virus | |
WO1989002277A3 (en) | Prophylaxis and therapy of acquired immunodeficiency syndrome | |
ATE105334T1 (de) | Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. | |
KR890700030A (ko) | 인플루엔자균(Haemophilus influenzae)의 백신 및 진단방법 | |
ES2143996T3 (es) | Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv. | |
ATE72400T1 (de) | Kreuzreaktive und schuetzende epitope von circumsporozoit-proteinen. | |
ATE71534T1 (de) | Vakzine. | |
NZ220500A (en) | Recombinant felv polypeptide; vaccine and expression vectors | |
ATE95422T1 (de) | Ein synthetisches nonapeptid zur verwendung als adjuvant. | |
EP0496787A4 (en) | Novel infectious bursal disease virus | |
SE8700466D0 (sv) | Vaccines against melanoma | |
ZA888580B (en) | New immunologically active synthetic peptides useful for preparing an antimalarial vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |